About 29 results found for searched term "IGF-1R" (0.134 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M2109 | AZD3463 | ALK |
| ALK/IGF1R inhibitor | ||
| AZD3463 is a novel ALK/IGF1R inhibitor with IC50 value of 22 nM. | ||
| M25276 | Ganitumab | IGF-1R |
| AMG 479; Human Anti-IGF1R Recombinant Antibody | ||
| Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer. | ||
| M50540 | IGF1Rtide | Others |
| IGF1Rtide can be used as a RET kinase substrate for RET kinase assays. | ||
| M1792 | XL228 | IGF-1R |
| XL-228 | ||
| XL228 is a potent multikinase small-molecule inhibitor of insulin-like growth factor type 1 receptor (IGF1R). | ||
| M1821 | OSI-906 | IGF-1R |
| Linsitinib | ||
| OSI-906 (Linsitinib) is a potent, selective, dual ATP-competitive tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) with IC50 values of 35 nM and 75 nM respectively. | ||
| M1957 | BMS-536924 | IGF-1R |
| Bms-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC50 of 100 nM and 73 nM, respectively. It also showed moderate inhibitory activity against Mek, Fak and Lck, but almost no inhibitory activity against Akt1 and MAPK1/2. | ||
| M2025 | PQ401 | IGF-1R |
| PQ401 is an insulin growth factor-1 receptor (IGF-1R) inhibitor. | ||
| M2192 | BMS-754807 | IGF-1R |
| Bms-754807 is a potent igf-1r /InsR reversible inhibitor with an IC50 of 1.8 nM/1.7 nM and also inhibits the activity of Met, RON, TrkA, TrkB, AurA and AurB with an IC50 value of 6,44,7,4, respectively. At 9 and 25 nM, it has almost no inhibitory activity against Flt3, Lck, MK2, PKA and PKC. | ||
| M2301 | NVP-TAE226 | FAK |
| TAE226 | ||
| Nvp-tae 226 (TAE226) is a potent atP-competitive dual FAK and IGF-1R inhibitor with IC50 of 5.5 nM and 140 nM, respectively. Nvp-tae 226 (TAE226) also effectively inhibited Pyk2, insulin receptor (InsR), with IC50 of 3.5 nM and 40 nM. | ||
| M2411 | Picropodophyllin(AXL1717) | IGF-1R |
| CAS# 17434-18-3;PPP | ||
| AXL1717 (picropodophyllin, Picropodophyllotoxin, PPP) is a non-competitive, potent, and specific inhibitor of IGF-1Rα/β with IC50 of 1 nM. | ||
| M3397 | AG-1024 | IGF-1R |
| Tyrphostin AG 1024 | ||
| AG-1024 (Tyrphostin) inhibits IGF-1R autophosphorylation with IC50 of 7 μM, is less potent to IR with IC50 of 57 μM and specifically distinguishes between InsR and IGF-1R (as compared to other tyrphostins). | ||
| M6168 | Ceritinib (LDK378) dihydrochloride | ALK |
| Ceritinib dihydrochloride | ||
| Ceritinib dihydrochloride (LDK378 dihydrochloride) is potent inhibitor against ALK with IC50 of 0.2 nM, shows 40- and 35-fold selectivity against IGF-1R and InsR, respectively. | ||
| M7067 | NVP ADW 742 | IGF-1R |
| ADW742; GSK 552602A; ADW | ||
| Nvp-adw742 (ADW742) is an orally active, selective igF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. Nvp-adw742 inhibited insulin receptor (InsR) with IC50 of 2.8 μM. Nvp-adw742 induces multipotent anti-proliferation/pro-apoptosis in tumor cells. | ||
| M20058 | WAY-278752 | IGF-1R |
| WAY-278752 inhibits the activity of IGF1R kinase. | ||
| M20306 | WAY-273339 | IGF-1R |
| WAY-273339 is a IGF-1R inhibitor. | ||
| M20319 | WAY-270250 | IGF-1R |
| WAY-270250 is a IGF-1R/SRC inhibitor. | ||
| M20352 | WAY-270252 | IGF-1R |
| WAY-270252 is a IGF-1R/SRC inhibitor. | ||
| M20615 | NT157 | IGF-1R |
| NT157, a selective inhibitor of IRS-1/2(insulin receptor substrate), has the potential to inhibit IGF-1R and STAT3 signaling pathways in cancer cells and stroma cells of TME leading to a decrease in cancer cell survival. | ||
| M21631 | Recombinant Human IGF-I (E.coli, 67AA) | Recombinant Proteins |
| Insulin-Like Growth Factor I; IGF1; Mecasermin | ||
| Insulin-like growth factor I (IGF1) binds IGF-1R, IGF-2R, and the insulin receptor and plays a key role in cell cycle progression, cell proliferation and tumor progression. Measured in a serum-free cell proliferation assay using MCF‑7 human breast cancer cells. The ED50 for this effect is 20-100 ng/ml. | ||
| M24531 | Dalotuzumab | IGF-1R |
| MK-0646; h7C10 | ||
| Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer drugs such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo. | ||
| M24540 | Teprotumumab | IGF-1R |
| Teprotumumab is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research. | ||
| M24705 | Istiratumab | IGF-1R |
| MM 141; MM-005 | ||
| Istiratumab (M-6495) is bispecific monoclonal antibody targeting IGF-1R and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers. | ||
| M25294 | Robatumumab | IGF-1R |
| Sch 717454; 19D12 | ||
| Robatumumab (Sch 717454) is an anti-human IGF-1R (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research. | ||
| M25296 | Figitumumab | IGF-1R |
| CP-751871 | ||
| Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC50 of 1.8 nM. | ||
| M25306 | Cixutumumab | IGF-1R |
| IMC-A12; NSC742460 | ||
| Cixutumumab (IMC-A12) is a humanized anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of IGF-IR. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer. | ||
| M25375 | Lonigutamab | IGF-1R |
| hz208F2-4 | ||
| Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody that can be used for the synthesis of antibody–drug conjugates (ADC). | ||
| M25376 | Lonigutamab ugodotin | IGF-1R |
| W0101 | ||
| Lonigutamab ugodotin (W0101) is a humanized IgG1κ monoclonal antibody targeting to IGF-1R. Lonigutamab ugodotin can be used in ADCs preparation. Lonigutamab ugodotin induces tumor regression in breast cancer models with IGF-1R overexpression without affecting normal cells. | ||
| M27783 | I-OMe-Tyrphostin AG 538 | IGF-1R |
| I-OMe-AG 538 | ||
| I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of IGF-1R (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells. I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC50 of 1 µM. | ||
| M30698 | AZ12253801 | IGF-1R |
| AZ12253801 is an ATP-competitive IGF-1R tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC50 of 17 nmol/L. The IC50 for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
